PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10910008-8	2000	After 6 months, gemfibrozil therapy versus placebo had a marked lipid-lowering effect, significantly decreased triglycerides (61%), VLDL cholesterol (72%), apoB (28%), and apoE (55%), and increased high-density lipoprotein (44%) and apoA-I (18%).	Gemfibrozil	16-27	apolipoprotein E	Homo sapiens	172-176	
10910008-9	2000	Furthermore, gemfibrozil affected the apoprotein composition of VLDL: total protein increased by 28%, the molar ratio of apoE to apoB decreased 64%, and apoE content decreased 55%.	Gemfibrozil	13-24	apolipoprotein E	Homo sapiens	121-125	
10910008-9	2000	Furthermore, gemfibrozil affected the apoprotein composition of VLDL: total protein increased by 28%, the molar ratio of apoE to apoB decreased 64%, and apoE content decreased 55%.	Gemfibrozil	13-24	apolipoprotein E	Homo sapiens	153-157